Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Subcommittee Approves Add’l Price Cut for Long-listed Drugs; Cut for Generics “Can’t Be Ruled Out”
December 19, 2011
- Expert Subcommittee Agrees to 2-Year Continuation of Trial of Premium for New Drug Development
December 19, 2011
- Iressa Osaka High Court Trial Expected to End in January 2012, March Ruling Possible
December 16, 2011
- MHLW Designates Everolimus, 3 Other Products as Orphan Drugs
December 16, 2011
- Public-Private Dialogue to Set Next Strategic Plan for Innovative Drug Discovery
December 15, 2011
- CSIMC Approves Draft Measures to Promote Generic Drug Use
December 15, 2011
- MHLW Notifies of Changes to Precautions for Warfarin Potassium Preparations
December 15, 2011
- ELD Issues Fully Revised GL for Clinical Evaluation of Sleep Medications
December 14, 2011
- Dr Nakamura’s Premature Retirement to Affect “Drug Discovery Support Organization” Project
December 14, 2011
- Government Decides FY2012 Tax Revision Outline, to Extend R&D Tax Break System by 2 Years
December 13, 2011
- Ruling Coalition Prioritizes Economic Evaluation, Other Programs for 2012 Special Budget Quota
December 12, 2011
- MHLW Issues Notification to Change Japanese Pronunciation of “Rivaroxaban” to “Rivah-roxaban”
December 12, 2011
- MOF Asks MHLW for Add’l 10% Price Cut for Long-listed Drugs
December 12, 2011
- Price Cuts for Long-listed Drugs Will Not Promote Generic Drug Use: Korosho in Negotiations with MOF
December 10, 2011
- 11 APIs/26 Products to Return Premium for New Drug Development
December 9, 2011
- MHLW Minister Komiyama Calls on Opposition to Join Efforts to Consider Third-Party Organization
December 9, 2011
- US FDA Begins Review of Risks of Serious Bleeding in Patients Taking Dabigatran
December 9, 2011
- NHI Drug Pricing Subcommittee to Apply 80% Rule for Combination Drugs to Injectables, Topical Drugs
December 8, 2011
- Gov’t Tax Commission Decides to Extend Temporary R&D Tax Credits
December 8, 2011
- CSIMC Submits Opinion on Medical Fee Revision Including Views of Both Healthcare Providers and Medical Bill Payers
December 8, 2011
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…